Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015775 | 0.87 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL13252942 | 0.87 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL6914307 | 0.87 | POLB (0.59) | POLBSTING1PDE3BPDE3APNP | |
| SCHEMBL30712246 | 0.85 | POLB (0.58) | POLBSTING1PDE3BPDE3APNP | |
| Deoxyguanosine SCHEMBL23225364 | 0.84 | POLB (0.67) | POLBPDE3APNPADORA3P2RY2 | |
| Deoxyguanosine SCHEMBL9396414 | 0.84 | POLB (0.67) | POLBPDE3APNPADORA3P2RY2 | |
| Deoxyguanosine SCHEMBL10068103 | 0.84 | POLB (0.67) | POLBPDE3APNPADORA3P2RY2 | |
| Deoxyguanosine SCHEMBL22992402 | 0.84 | POLB (0.67) | POLBPDE3APNPADORA3P2RY2 | |
| SCHEMBL8416538 | 0.84 | POLB (0.57) | POLBSTING1PDE3BPDE3APNP | |
| Deoxyguanosine SCHEMBL20615 | 0.84 | POLB (0.67) | POLBPDE3APNPADORA3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412370-A1 | NUCLEOSIDE PYROPHOSPHATE AND TRIPHOSPHATE ANALOGS AND RELATED COMPOUNDS AS THERAPEUTIC AGENTS | Sri International (US) | 2004-04-28 | — | — | EP | claimed |
| US-20020142414-A1 | Process for the preparation of protease inhibitors | UCP GEN-PHARMA AG (CH) | 2002-10-03 | — | — | US | claimed |
| WO-2001014401-A1 | NUCLEOSIDE PYROPHOSPHATE AND TRIPHOSPHATE ANALOGS AND RELATED COMPOUNDS AS THERAPEUTIC AGENTS | SRI INTERNATIONAL (US) | 2001-03-01 | — | — | WO | claimed |
| EP-0146785-A1 | Process for the preparation of protease inhibitors | CIBA-GEIGY AG (CH) | 1985-07-03 | — | — | EP | claimed |
| JP-57206698-A | — | — | None | — | — | JP | disclosed |
| JP-57206696-A | — | — | None | — | — | JP | disclosed |
| US-20020142414-A1 | Process for the preparation of protease inhibitors | UCP GEN-PHARMA AG (CH) | 2002-10-03 | — | — | US | disclosed |
| US-6342373-B1 | ACETYL DERIVATIVES OF AMINO ACID SEQUENCES, CULTURES OF ESCHERICHIA OR SACCHAROMYCES AND EXPRESSION VECTORS | UCP GEN-PHARMA AG (CH) | 2002-01-29 | — | — | US | disclosed |
| US-5728549-A | GENE EXPRESSION VECTORS WITH CONTROLLING SEQUENCES OF DNA | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| US-5422249-A | Polypeptides | CIBA-GEIGY CORPORATION (US) | 1995-06-06 | — | — | US | disclosed |
| EP-0168342-B1 | PROCESS FOR THE PREPARATION OF THROMBIN INHIBITORS | CIBA-GEIGY AG (CH) | 1991-07-03 | — | — | EP | disclosed |
| EP-0146785-B1 | PROCESS FOR THE PREPARATION OF PROTEASE INHIBITORS | CIBA-GEIGY AG (CH) | 1990-02-07 | — | — | EP | disclosed |
| EP-0168342-A1 | Process for the preparation of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| EP-0146785-A1 | Process for the preparation of protease inhibitors | CIBA-GEIGY AG (CH) | 1985-07-03 | — | — | EP | disclosed |
| JP-S57206698-A | DODECANUCLEOTIDE AND ITS PREPARATION | EISAI CO LTD | 1982-12-18 | — | — | JP | disclosed |
| JP-S57206696-A | DODECANUCLEOTIDE AND ITS PREPARATION | EISAI CO LTD | 1982-12-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142414-A1 | Process for the preparation of protease inhibitors | EGLN2, EGLN1, PREP | POLB 549/4885STING1 453/4885PDE3B 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.